drugset / Trial / NCT03126097

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

NCT03126097

Phase 1 Terminated 18 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of single and multiple doses of JNJ-64155806 on the steady-state pharmacokinetics (PK) of ethinylestradiol and drospirenone and vice versa in healthy female participants.

Timeline

Start
2017-04-13
Primary completion
2017-05-26
Completion
2017-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64155806 Unknown 150 mg
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 0.02 mg Oral

Indications

No indication recorded.